# Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

> **NCT07009600** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 124 (actual)

## Conditions studied

- Gastric Cancer Stage IV

## Interventions

- **DRUG:** immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)

## Key facts

- **NCT ID:** NCT07009600
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009600, "Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07009600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*